By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



30 Worcester Road

Toronto  Ontario  M9W 5X2  Canada
Phone: 416-798-3001 Fax: 416-798-3007



Company News
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015 10:26:01 AM
IntelliPharmaCeutics Reports Director Election Results 4/22/2015 2:01:18 PM
IntelliPharmaCeutics Announces First Quarter 2015 Results 4/15/2015 3:29:17 PM
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015 12:42:39 PM
IntelliPharmaCeutics Announces 2014 Year End Results With A 48% Reduction In Operating Loss 2/23/2015 7:55:51 AM
IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA (TEVA) For An Extended Release Oral Drug Product Candidate 2/2/2015 7:54:49 AM
IntelliPharmaCeutics Notes Launch Of 5mg Strength Of Focalin XR(R) Generic By Teva Pharmaceutical Industries Limited (TEVA) 11/20/2014 10:33:07 AM
IntelliPharmaCeutics Reports That The FDA Has Given Its Toronto Manufacturing Facility An "Acceptable" Classification 10/27/2014 7:48:06 AM
IntelliPharmaCeutics Reports Positive Results From A Series Of Phase I Clinical Trials Of Regabatin™ XR (Pregabalin Extended-Release) 10/23/2014 7:17:54 AM
IntelliPharmaCeutics Announces Third Quarter 2014 Results 10/16/2014 7:31:20 AM